Neupogen (filgrastim) is a protein pharmaceutical. Filgrastim was first approved as Neupogen on 1991-02-20. It is used to treat neutropenia in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation, neoplasms, and neutropenia. It is known to target macrophage colony-stimulating factor 1 receptor and granulocyte colony-stimulating factor receptor.
|Indication||hematopoietic stem cell transplantation, neoplasms, neutropenia|
|Drug Class||Colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF)|